Study on weight loss in ALS patients from France and Germany
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at why some people with ALS lose weight and what factors are involved. It follows patients in France and Germany to better understand weight changes and help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recently been diagnosed with ALS.
- You are 18 years or older.
- You are being treated at one of the participating ALS centers in France or Germany.
- You are willing to take the medication Riluzole during the study.
- You can understand the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells (called macrophages) from people with ALS and certain related movement or nerve conditions. It aims to better understand how the disease works and may help researchers design future treatments.
This study continuously measures activity and movement in people with ALS and in control participants. It aims to better understand how muscle disease changes day-to-day function, which may help improve future monitoring or care.
This trial collects blood and spinal fluid samples from people being checked for ALS. The goal is to find clues (biomarkers) in tiny particles from nerve cells that could help doctors better understand and diagnose ALS.
This study uses a wearable device to track movement patterns in people with ALS. It aims to better understand how the disease affects movement over time, which may help improve care.
This study looks at the bacteria in your gut (microbiome) to see if they are linked to different symptoms or types of ALS. It may help doctors understand more about the disease and could lead to better treatments in the future.
This study looks at how much burden (stress and day-to-day strain) ALS creates for both the patient and the main caregiver. It may help shape better ways to support families facing ALS over time.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.